Daily Newsfeed
Tuesday, October 27, 2026
KNMP announces that the guidance on the interaction between levothyroxine and GLP-1 agonists is expanded from 1 November. Brand and medical teams in the obesity and diabetes category should check that their HCP materials reflect the updated Dutch guidance.
knmp.nl →The budget debate covered the DNA medication pass, waiting times in the medicines gateway and the planned Future-Proof Medicines System. Access and pricing timelines remain the core context for Dutch launch communication.
knmp.nl →CBG-MEB: requests to withdraw human medicines effective 31 December must arrive by 1 November to avoid the 2027 annual fee. Portfolio and lifecycle teams have a hard deadline this week.
cbg-meb.nl →At Health~Holland's 15th-anniversary event, STZ director Danique Roodnat argued for closer ties between healthcare and industry. Useful framing for partnership and collaboration storytelling in the Dutch market.
health-holland.com →EMA's human medicines committee recommended six new medicines and five extensions of indication. A useful pipeline view for launch-readiness planning.
ema.europa.eu →EMA presents a once-daily tablet as an alternative to existing oral and injectable GLP-1 medicines. A more crowded category makes differentiation messaging essential.
ema.europa.eu →The recommendation followed a phased review designed to speed up assessment of a medicine addressing unmet need. Expect launch preparation and compliant evidence-led messaging to ramp up.
ema.europa.eu →EFPIA (15 October) advocates one streamlined regulatory route for AI-enabled medical technologies. Relevant for anyone planning digital and AI-supported health solutions in Europe.
efpia.eu →The UK PMCPA found multiple code breaches on an Otsuka-involved event webpage but did not impose its harshest penalty. Third-party event content still needs rigorous sign-off.
fiercepharma.com →AbbVie is promoting the economic argument for treating Parkinson's disease early with a subcutaneous therapy. Health-economic storytelling is becoming a core part of brand messaging.
fiercepharma.com →PharmaVoice reports that drugmaker gifts to physicians are associated with higher prescription volume but poorer prescribing quality. A timely reminder for HCP engagement and transparency policies.
pharmavoice.com →Eli Lilly is combating online illicit sellers of retatrutide while the drug is still in clinical trials. Brand protection and patient-safety communication now start pre-launch.
pharmavoice.com →KNMP's expanded interaction guidance, a new oral option at EMA and Lilly's pre-launch brand protection show a crowded, closely watched category where accuracy and differentiation matter.
The PMCPA's Otsuka ruling and new research on physician gifts underline that event pages, partners and HCP engagement all fall within compliance scrutiny.
Dutch reimbursement waits, EMA's phased reviews and AbbVie's economic case for early treatment point to value and access narratives sitting beside efficacy.